tezosentan has been researched along with milrinone in 2 studies
| Studies (tezosentan) | Trials (tezosentan) | Recent Studies (post-2010) (tezosentan) | Studies (milrinone) | Trials (milrinone) | Recent Studies (post-2010) (milrinone) |
|---|---|---|---|---|---|
| 157 | 29 | 33 | 1,605 | 235 | 452 |
| Protein | Taxonomy | tezosentan (IC50) | milrinone (IC50) |
|---|---|---|---|
| Phosphodiesterase | Bos taurus (cattle) | 1 | |
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.3 | |
| High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A | Homo sapiens (human) | 0.3 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.52 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 4.7 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | 6 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | 6 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | 6 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | 3.15 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 1.8674 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 1.8177 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Bos taurus (cattle) | 5 | |
| Phosphodiesterase | Sus scrofa (pig) | 0.843 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Mehra, MR | 1 |
1 review(s) available for tezosentan and milrinone
| Article | Year |
|---|---|
Optimizing outcomes in the patient with acute decompensated heart failure.
Topics: Biomarkers; Cardiotonic Agents; Diuretics; Heart Failure; Hemodynamics; Humans; Hydrazones; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroglycerin; Pyridazines; Pyridines; Risk Assessment; Simendan; Tetrazoles; Therapeutics; Troponin; Vasodilator Agents; Ventricular Function, Left; Ventricular Pressure | 2006 |
1 other study(ies) available for tezosentan and milrinone
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |